INM has started off solid and it may just be the start.

SmallCapFirm

Up Approximately 11% Early, Past Champ (INM) Could Be Run-Ready As Today's Breaking News Circulates

Edison Group INM Price Target - $6.00

June 9th

SCF Readers,

INM has started off solid and it may just be the start.

Up approximately 11% while hitting a high of $.75+, INM is riding high early.

Why? The company dropped huge news this morning.

Check it out:

InMed Launches TH-CV, Expanding its Portfolio of Rare Cann-a-binoids for the Health and Wellness Sector

From the article:

We are very excited to launch our highly anticipated d-9-TH-CV and further enhance BayMedica’s growing product portfolio,” stated Shane Johnson, MD, SVP and General Manager of BayMedica. “TH-CV is one of the few rare cann-a-binoids that has been researched in early clinical trials for various therapeutic effects, fueling significant interest by end-product manufacturers and consumers alike. In anticipation of this launch, we have expanded internal sales and marketing infrastructure, developed new distribution channels and optimized the supply chain to ensure a consistent and reliable supply of a high quality product. As this market continues to mature, we are well positioned to be a leading supplier of rare cann-a-binoids to the health and wellness industry. We currently have several high-value, rare cann-a-binoids in various stages of commercial development and will continue to expand our cann-a-binoid portfolio over the coming years."

On top of that, INM is trading above both its 5-Day Simple Moving Average (SMA) and its 5-Day Exponential Moving Average (EMA).

If support continues to build, it may give INM the juice to push through its 13-Day EMA which it is battling with currently.

And if that happens, the market could take serious interest in this past champ.

Take a moment now to get INM on your radar and read my initial report below.

-----

It's official. Time's up

Coming off a Tuesday profile that shot approximately 19% from an open of $.86+ to a high of $1.03, I felt compelled to step up my game and bring you an idea with even more breakout potential.

A past champ is what I found.

Brought to your attention back on April 21st, this Nasdaq profile opened at $.9547 and ran to a high of $1.41 that day.

When the dust settled, this breakout idea had run approximately 47% intraday.

Now I want you to get it back on your radar again. Here's why...

Between a major $6.00 analyst target from the Edison Group, a very low float, and some key, game-changing news announcements over the past couple months, it could be poised for another vertical run.

That's why for Thursday, June 9th, there is only one Nasdaq profile to have on your radar:

*InMed Pharmaceuticals Inc. (INM)*

InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cann-a-binoids.

Together with its subsidiary BayMedica LLC, the Company has unparalleled cann-a-binoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness.

InMed is also a clinical-stage company developing a pipeline of rare cann-a-binoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cann-a-binoid-based pharmaceutical dr-ugs.

And right now it has several key potential catalyst that could fuel a vertical move in the near term. Check them out:

No. 1 - Research Firm Edison Group Provides Huge $6.00 Price Target

No. 2 - Another Low Float Profile

No. 3 - Company Expands Patent Portfolio And Advances Collaboration Agreement

No. 4 - Commercialization Of CB-DV Product Could Provide Major Boost

But more on those in a second...

InMed Pharmaceuticals (INM): Unparalleled Cann-a-binoid Manufacturing Expertise

To put it simply, no one manufacturing approach fits all.

Multiple avenues are needed to select the most effective manufacturing method based on target cann-a-binoids and the appropriate quality specifications for the desired market segment.

And THIS is where InMed has a leg up on the competition. By acquiring BayMedica, the company has 3 different types of manufacturing avenues:

image

Now, the company has already launched rare cann-a-binoids in CBC and CBT to multiple business customers in the consumer health and wellness space, but InMed’s pipeline could be really big news moving forward.

But more important is the scale and purity of the CB-DV and TH-CV. CB-DV is structurally similar to CB-D (cann-a-bidiol). Like CB-D, CB-DV is not intoxicating when isolated, so it won’t cause the euphoric high associated with high-TH-C cann-a-bis.

That means there is ZERO RISK of having or being associated with a controlled substance. Just take a look and see what the future may hold:

image

Just know, there are over 100 rare cann-a-binoids out there. This could be only the start of something even bigger.

Read The Full Company Presentation Here.

-----

Right now, INM has several potential catalysts to be aware of. Here they are:

No. 1 INM Potential Catalyst - Research Firm Edison Group Provides Huge $6.00 Price Target

"Huge" might be an understatement here.

Edison group slapped a $6.00 price target on INM last month which provides this profile with a stunning 500+% potential upside from Wednesday's closing valuation.

On top of that, they have even given INM a "Bull" estimate target of $16.00.

Here's some highlights from the report:

Company description: A platform of rare cann-a-binoids

InMed Pharmaceuticals is a North American-based biopharmaceutical company focused on researching, developing and manufacturing cann--abinoids for the therapeutic market, and also recently entered the cann-a-binoid commercial sales segment through its BayMedica acquisition. Through its pharma program, it is developing a proprietary pipeline of cann-a-binoids to treat target diseases. Its lead program is INM-755, a tropical cream using CBN for treating EB, which is currently enrolling patients for Phase II trials. It is also developing INM-088 for glaucoma, which is in a preclinical stage, and InMed is preparing for a Food and Drug Administration (FDA) preinvestigational new drug meeting (pre-IND) in Q2 CY22.

In parallel with its pharma program, it is developing its own proprietary manufacturing program IntegraSyn, an enzymatic process that uses E. coli to individually manufacture each of the c 140 cann-a-binoids. INM is also focusing on scaling up the IntegraSyn process to larger batch sizes in advance of commercial scale production. Furthermore, its product library of rare cann-a-binoid analogs creates a commercialization opportunity, while BayMedica’s aptitude in chemical synthesis and yeast biosynthesis to manufacture cann-a-binoids complements InMed’s capabilities in using E. coli through its IntegraSyn manufacturing platform.

With its recent acquisition of BayMedica, InMed is evolving from a pure-play firm focused on pharma R&D to a more diversified one with commercial sales in the health and wellness market, and we now expect it to exhibit near-term revenue generation combined with the longer-term value of its pharma drug development programs.

Valuation: Base scenario at US$85m, or US$6.0 per share

We have considered three scenarios in our risk-adjusted net present value (NPV) analysis. Our base case company valuation is US$85m, or US$6.0 per basic share, while the bull and bear scenarios are US$16.0 per basic share (US$227m) and US$1.5 per basic share (US$21m), respectively, compared to the previous US$20.53 per basic share or US$290m. The change in valuation is primarily due to a reassessment of both the base-case market share for the biosynthesis platform and the INM-755 product, as well as more conservative pricing estimates. In our model, we evaluated three scenarios where InMed could achieve different portions of its addressable market if its biosynthesis process is successfully validated and scaled to commercial levels. We also considered the market penetration InMed’s EB treatment could achieve, as well as the sales growth of the health & wellness products and potential price pressures as competitors enter the market. Given the early stage of its proprietary pipeline, the majority of the valuation stems from its biosynthesis platform, which targets a sizable and growing market for rare cann-a-binoids, and its potential EB treatment (INM-755).

-----

No. 2 INM Potential Catalyst - Another Low Float Profile

According to the Yahoo Finance website, INM has a low float.

The website reports this profile to have approximately 14.25Mn shares in its float.

Why is that important? It's important on one crucial level. Volatility.

With so few shares available for trading, other potential catalysts (like big news) could spark a vertical move in the short-term.

-----

No. 3 INM Potential Catalyst - Company Expands Patent Portfolio And Advances Collaboration Agreement

InMed Expands Patent Portfolio with Novel Cann-a-binoid Analogs and Advances Collaboration Agreement with Leading Cann-a-binoid Research Expert

  • Expands library of proprietary cann-a-binoid analogs for pharma R&D
  • Research collaboration initiated to screen analogs for therapeutic uses

VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cann-a-binoids, is pleased to announce the publication of a patent application in North America for several cann-a-binoid analogs. This patent application has broad claims directed to their molecular structure, uses and methods of manufacturing.

Entitled “Cann-a-binoid Analogs and Methods for their Preparation”, the patent application describes several new cann-a-binoid-related chemical compounds that have not been previously described. If granted, the broad patent application allows for the creation of several variations of novel cann-a-binoid compounds, producing a robust library of proprietary new chemical entities (‘NCEs’).

Scientists at BayMedica, LLC, InMed’s subsidiary in the US, designed and produced these cann-a-binoid analogs. These NCEs are expected to offer similar or improved therapeutic effects compared to their parent (naturally occurring) cann-a-binoid with modifications that may make them preferred candidates to treat specific diseases.

Eric Hsu, SVP, Pre-Clinical Research and Development for InMed commented; “We believe rare cann-a-binoids hold tremendous therapeutic potential that may address a number of unmet medical needs. This patent covers the selective modification of naturally occurring cann-a-binoids to target specific properties for pharmaceutical development. Such patent protection is an important component to ensure long-term commercial exclusivity as we continue to invest in R&D."

...

Read the full article here.

-----

No. 4 INM Potential Catalyst - Commercialization Of CB-DV Product Could Provide Major Boost

InMed Commercializes Cann-a-bidivarin (CB-DV), Expanding its Rare Cann-a-binoid Portfolio for the Health and Wellness Sector

  • Expands rare cann-a-binoid portfolio beyond current C-B-C and C-B-T
  • Releases White Paper outlining research into the therapeutic potential of CB-DV

VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cann-a-binoids, is pleased to announce it has launched B2B sales of the rare cann-a-binoid cann-a-bidivarin (“CB-DV”) to wholesalers, suppliers and end-product manufacturers in the health and wellness sector through its US subsidiary, BayMedica LLC.

Ensuring a reliable, large volume source of highly pure, bioidentical CB-DV is an important step forward in the health and wellness sector. CB-DV has been researched for its therapeutic potential in several disease areas such as autism spectrum disorder,” said Shane Johnson, MD, SVP and General Manager of BayMedica. “Whether you are a researcher or product developer at a multinational consumer package goods (‘CPG’) company, the ability to access highly pure and consistent active ingredients, free from contaminants typically found in plant-sourced cann-a-binoids such as pesticides, heavy metals, or potentially even T-H-C, is a fundamental requirement. BayMedica’s cann-a-binoid manufacturing technologies provides exactly that value and we are excited to continue to introduce to the market additional rare cann-a-binoids that have previously not been abundantly accessible, including adding TH-CV to our portfolio in the immediate future.

...

Read the full article here.

-----

Nasdaq Profile Recap - Top 4 INM Potential Catalysts

No. 1 - Research Firm Edison Group Provides Huge $6.00 Price Target

No. 2 - Another Low Float Profile

No. 3 - Company Expands Patent Portfolio And Advances Collaboration Agreement

No. 4 - Commercialization Of CB-DV Product Could Provide Major Boost

-----

Coverage is officially reinitiated on INM. When you have time later, do this:

image

Get INM on your radar now.

Sincerely,

Axel Adams

Editor, SCF


Source 1


(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)​

StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company (SWN Media LLC has recently retained ownership of StockNewsWire LLC). Disclosure: Make sure to always do your own research and due diligence on any day and swing trade profile I bring to your attention. I am not a license d finan.cial advise r. All potential percentage gains are based on from the low to the high of day. SmallCapFirm's full disclosure is to be read and fully understood before using SmallCapFirm's website, or joining SmallCapFirm's email or text list. By viewing SmallCapFirm's website and/or reading SmallCapFirm's email or text newsletter you are agreeing to SmallCapFirm's full disclosure which can be read at: smallcapfirm.com/disclosure StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company (SWN Media LLC has recently retained ownership of StockNewsWire LLC). An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns an interest in the limited liability company that owns and operates fierceinvestor . com (“FI”), an interest in the limited liability company that owns and operates stockstreetwire . com (SSW), and an interest in the limited liability company that owns and operates nasdaqwirenews . com (NWN) . From time to time, StockWireNews, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SmallCapFirm (SCF) has been hired for a period beginning on 4/21/22 and ending on 4/22/22 to publicly disseminate information about (INM) via Website, Email and SMS. SWN Media LLC was paid thirty thousand USD via bank wire transfer. We own zero shares of (INM). Pursuant to an agreement between SWN Media LLC and TD Media LLC, SmallCapFirm (SCF) has been hired for a period beginning on 6/9/22 and ending on 6/10/22 to publicly disseminate information about (INM) via Website, Email and SMS. SWN Media LLC was paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (INM). To date we have now been compensated a total of fifty-seven thousand five hundred USD via bank wire transfer to disseminate information about (INM).